Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV

By: via Benzinga
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that results from a 12-patient phase I study of Inovio's HIV immunotherapy, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.